AVIR
Atea Pharmaceuticals, Inc. NASDAQ Listed Oct 30, 2020$4.39
+0.80%
vs $4.36
Mkt Cap $351.7M
52w Low $2.78
44.0% of range
52w High $6.45
50d MA $4.96
200d MA $4.11
P/E (TTM)
—
EV/EBITDA
—
P/B
1.3x
Debt/Equity
0.0x
ROE
-57.5%
P/FCF
-2.7x
RSI (14)
39.50
ATR (14)
$0.20
Beta
0.16
50d MA
$4.96
200d MA
$4.11
Avg Volume
331.2K
Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focused on discovering, developing, and commercializing antiviral therapeutics for patients suffering from viral infections. Its lead product candidate is AT-527, an antiviral drug candidate that is in Phase II clinical trial for the treatment of patients with COVID-19. The company also develops AT-752, an oral purine nucleoside prodrug product candidate, which has completed Phase Ia clinical trial for the treatment of dengue; AT-777, an NS5A inhibitor; AT-787, a co-formulated, oral, pan-genotypic fixed dose combination of AT-527 and AT-777 for the treatment of hepatitis C virous (HCV); and AT-281, a pharmaceutically acceptable salt for the treatment or prevention of an RNA viral infection, including dengue fever, yellow fever, Zika virus, and coronaviridae viral infection, as well as Ruzasvir, an investigational oral, pan genotypic NS5A inhibitor for the treatment of chronic HCV infection. It has a license agreement with Merck & Co, Inc. for development and commercialization of ruzasvir for the treatment of HCV. Atea Pharmaceuticals, Inc. was incorporated in 2012 and is headquartered in Boston, Massachusetts.
125 Summer Street · Boston, MA 02110 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 5, 2026 | AMC | -0.49 | -0.57 | -16.3% | 5.30 | -9.1% | +11.1% | +4.4% | -1.6% | +0.8% | +0.0% | — |
| Nov 12, 2025 | AMC | -0.46 | -0.53 | -15.2% | 3.50 | -14.3% | -12.6% | -3.3% | +2.0% | +1.0% | +3.3% | — |
| Aug 7, 2025 | AMC | -0.46 | -0.44 | +4.3% | 3.46 | +5.2% | -2.3% | +3.8% | +0.0% | -0.3% | -0.3% | — |
| May 12, 2025 | AMC | -0.56 | -0.40 | +28.6% | 2.96 | -2.0% | -11.1% | -3.0% | +1.6% | +5.8% | +2.6% | — |
| Mar 6, 2025 | AMC | -0.35 | -0.40 | -14.3% | 3.00 | -3.7% | -0.3% | -2.3% | +0.0% | +6.2% | -1.3% | — |
| Nov 7, 2024 | AMC | -0.49 | -0.37 | +24.5% | 3.44 | +1.5% | +1.7% | -4.0% | -0.9% | +0.6% | -1.2% | — |
| Aug 7, 2024 | AMC | -0.76 | -0.48 | +36.8% | 3.27 | +0.3% | +7.0% | -3.7% | -0.6% | +9.3% | -1.6% | — |
| May 14, 2024 | AMC | -0.61 | -0.75 | -23.0% | 3.96 | -3.8% | -6.3% | -0.3% | -1.4% | -1.4% | +0.3% | — |
| Feb 28, 2024 | AMC | -0.50 | -0.47 | +6.0% | 4.37 | +3.0% | -1.4% | +3.2% | -9.2% | -1.2% | +1.0% | — |
| Nov 8, 2023 | AMC | -0.48 | -0.40 | +16.7% | 3.29 | -4.0% | -9.1% | -3.0% | -0.7% | +4.2% | -1.7% | — |
| Aug 8, 2023 | AMC | -0.47 | -0.34 | +27.7% | 3.41 | +2.6% | +3.8% | -4.2% | +0.6% | -0.9% | -0.9% | — |
| May 8, 2023 | AMC | -0.48 | -0.43 | +10.4% | 3.40 | -2.9% | -2.6% | +0.3% | -0.3% | -1.8% | +6.2% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 9 | Evercore ISI | Maintains | Outperform → Outperform | — | $5.89 | $5.95 | +1.0% | +4.4% | -1.6% | +0.8% | +0.0% | +0.0% |
| Apr 11 | Morgan Stanley | Maintains | Equal Weight → Equal Weight | — | $2.69 | $2.70 | +0.4% | +0.7% | +8.5% | -4.1% | +6.4% | -1.0% |
| Aug 13 | Morgan Stanley | Upgrade | Underweight → Equal Weight | — | $3.35 | $3.55 | +6.0% | +9.3% | -1.6% | +3.9% | -1.6% | +3.8% |
| Aug 10 | JP Morgan | Downgrade | Neutral → Underweight | — | $3.54 | $3.43 | -3.1% | -4.2% | +0.6% | -0.9% | -0.9% | +0.3% |
| Mar 16 | JP Morgan | Maintains | Neutral → Neutral | — | $3.65 | $3.65 | +0.0% | +0.8% | +2.4% | -7.2% | -2.3% | -3.5% |
| Jan 27 | SVB Leerink | Maintains | Market Perform → Market Perform | — | $4.57 | $4.55 | -0.4% | +0.7% | +0.2% | +0.4% | -0.2% | +2.6% |
| Jan 24 | Morgan Stanley | Maintains | Underweight → Underweight | — | $4.75 | $4.64 | -2.3% | -4.2% | -1.1% | +1.6% | +0.7% | +0.2% |
| Aug 15 | Morgan Stanley | Maintains | Underweight → Underweight | — | $8.41 | $8.38 | -0.4% | +2.0% | +0.7% | -0.9% | -2.1% | -1.7% |
| Mar 2 | JP Morgan | Maintains | Neutral → Neutral | — | $6.46 | $6.44 | -0.3% | +2.2% | -4.5% | -8.7% | +2.4% | +1.4% |
| Mar 1 | SVB Leerink | Maintains | Market Perform → Market Perform | — | $6.34 | $7.00 | +10.4% | +1.9% | +2.2% | -4.5% | -8.7% | +2.4% |
| Feb 16 | SVB Leerink | Maintains | Market Perform → Market Perform | — | $6.42 | $6.39 | -0.5% | -0.9% | -4.7% | -2.3% | -0.2% | -1.9% |
| Jan 6 | Morgan Stanley | Downgrade | Equal Weight → Underweight | — | $8.30 | $7.80 | -6.0% | -6.5% | -1.5% | +0.5% | +2.7% | -2.9% |
| Nov 18 | SVB Leerink | Downgrade | Outperform → Market Perform | — | $8.69 | $8.41 | -3.2% | -0.8% | -5.9% | -1.8% | -3.6% | +0.1% |
| Oct 20 | JP Morgan | Downgrade | Overweight → Neutral | — | $13.82 | $13.83 | +0.1% | -4.2% | -3.7% | -0.2% | -0.1% | -2.6% |
| Oct 20 | SVB Leerink | Maintains | Outperform → Outperform | — | $13.82 | $13.83 | +0.1% | -4.2% | -3.7% | -0.2% | -0.1% | -2.6% |
| Oct 5 | Morgan Stanley | Downgrade | Overweight → Equal Weight | — | $44.59 | $44.24 | -0.8% | -5.0% | -5.9% | +2.9% | -2.4% | -3.0% |
| Sep 9 | SVB Leerink | Maintains | Outperform → Outperform | — | $27.70 | $28.75 | +3.8% | +3.5% | -0.2% | -2.5% | -0.6% | -6.3% |
| Aug 18 | Morgan Stanley | Maintains | Overweight → Overweight | — | $28.74 | $28.93 | +0.7% | +1.6% | +0.9% | +0.6% | +0.4% | +0.1% |
| Jun 3 | Morgan Stanley | Maintains | Overweight → Overweight | — | $20.57 | $20.74 | +0.8% | -0.2% | +4.9% | +11.1% | -1.7% | +4.3% |
| Apr 6 | Morgan Stanley | Maintains | Overweight → Overweight | — | $58.71 | $59.26 | +0.9% | +0.6% | -3.2% | -0.7% | -0.5% | -2.1% |
| Jan 29 | JP Morgan | Maintains | Overweight → Overweight | — | $59.14 | $61.23 | +3.5% | +23.4% | +3.5% | +10.9% | +5.3% | -7.1% |
| Nov 25 | Evercore ISI | Maintains | Outperform → Outperform | — | $34.07 | $34.50 | +1.3% | -0.8% | +1.9% | -3.3% | -3.9% | -4.4% |
| Nov 24 | Morgan Stanley | Maintains | Overweight → Overweight | — | $33.54 | $35.76 | +6.6% | +1.6% | -0.8% | +1.9% | -3.3% | -3.9% |
| Date | Insider | Title | Type | Shares | Price | Value | Owned After | D1% | D5% |
|---|---|---|---|---|---|---|---|---|---|
| May 18, 2025 | Murphy Polly A. | — | Buy | 6,100 | $4.17 | $25K | 92,145 | +1.19% | +3.96% |
Institutional (13F) — Top 20
All ↗
| # | Manager | Shares | Value | Chg | Period |
|---|---|---|---|---|---|
| 1 | Fmr Llc | 11,950,772 | $64M | Added | Mar 2026 |
| 2 | Bml Capital Management, Llc | 7,058,657 | $38M | Reduced | Mar 2026 |
| 3 | Vanguard Capital Management Llc | 3,246,124 | $17M | New | Mar 2026 |
| 4 | Tang Capital Management Llc | 4,814,700 | $17M | — | Dec 2025 |
| 5 | Two Sigma Investments, Lp | 1,864,164 | $10M | Added | Mar 2026 |
| 6 | Acadian Asset Management Llc | 1,582,817 | $9M | Added | Mar 2026 |
| 7 | Rosalind Advisors, Inc. | 1,171,855 | $6M | New | Mar 2026 |
| 8 | Renaissance Technologies Llc | 1,166,400 | $6M | Reduced | Mar 2026 |
| 9 | Jpmorgan Chase & Co | 940,157 | $5M | Reduced | Mar 2026 |
| 10 | Morgan Stanley | 1,312,150 | $5M | Added | Dec 2025 |
| 11 | Northern Trust Corp | 585,025 | $3M | Added | Mar 2026 |
| 12 | Vanguard Portfolio Management Llc | 557,579 | $3M | New | Mar 2026 |
| 13 | D.e. Shaw & Co | 379,314 | $2M | Reduced | Mar 2026 |
| 14 | Millennium Management | 349,932 | $2M | Reduced | Mar 2026 |
| 15 | Banque Pictet & Cie Sa | 345,077 | $2M | — | Mar 2026 |
| 16 | Irenic Capital Management Lp | 301,699 | $2M | New | Mar 2026 |
| 17 | Peapod Lane Capital Llc | 272,820 | $1M | Reduced | Mar 2026 |
| 18 | Nuveen, Llc | 243,103 | $1M | Added | Mar 2026 |
| 19 | Cm Management, Llc | 355,000 | $1M | Reduced | Dec 2025 |
| 20 | Arrowstreet Capital, Limited Partnership | 210,542 | $1M | New | Mar 2026 |
Mutual Funds / ETFs (N-PORT) — Top 20
All ↗
Valuation
Market Cap
$351.7M
Enterprise Value
$53.5M
P/E (TTM)
—
Forward P/E
—
PEG Ratio
0.61x
P/B
1.30x
P/S
—
P/FCF
-2.69x
EV/EBITDA
—
Shares Out
81.5M
Financials (TTM)
Revenue
$0
Net Income
-$169.5M
EBITDA
-$179.9M
Free Cash Flow
-$132.0M
Op Cash Flow
-$132.0M
EPS Basic
$-1.94
EPS Diluted
$-2.11
EPS Forward
$-1.93
Gross Margin
—
Op Margin
—
Net Margin
—
Balance Sheet
Total Assets
$315.2M
Total Liab.
$39.8M
Total Equity
$275.4M
Cash
$301.8M
LT Debt
$0
Book Value/Sh
$3.38
Debt/Equity
0.00x
Current Ratio
7.82
Quick Ratio
7.82
Returns & Growth
ROE
-57.5%
ROA
-50.2%
ROIC
-63.0%
Rev Growth YoY
+0.0%
EPS Growth YoY
+3.0%
Price Returns
2W
+9.4%
1M
-15.2%
3M
-0.2%
6M
+50.6%
12M
+57.2%
Technicals
52W High
$6.45
52W Low
$2.78
50d MA
$4.96
200d MA
$4.11
RSI (14)
39.50
ATR (14)
$0.20
Beta
0.16
Avg Volume
331K
Dividends
Div Rate
$0.00
Div Yield
—
Frequency
—
Ex-Div Date
—
Analyst Price Targets
Consensus
$10.00
High
$10.00
Low
$10.00
Median
$10.00
Data updated apr 24, 2026 7:59pm
· Source: financialmodelingprep.com